Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raphael Mwangi

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Blood Cancer Journal|January 15, 2020
High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?Priyanka A Pophali, Lisa M Marinelli, Rhett P Ketterling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?Arushi Khurana, Raphael Mwangi, Grzegorz S Nowakowski, et al.
American Heart Journal|December 25, 2015
Trends and predictors of repeat catheter ablation for atrial fibrillationMohammed A Al-Hijji, Abhishek J Deshmukh, Xiaoxi Yao, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2019
Variation in Treatment Practices for Subclinical Hypothyroidism in Pregnancy: US National AssessmentSpyridoula Maraka, Raphael Mwangi, Xiaoxi Yao, et al.
Blood Advances|September 28, 2022
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosisSanjal H Desai, Raphael Mwangi, Wern Lynn Ng, et al.
Blood Cancer Journal|July 18, 2021
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab eraArushi Khurana, Raphael Mwangi, Stephen M Ansell, et al.
American Journal of Hematology|October 14, 2024
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screeningSuheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, et al.
Hematological Oncology|October 28, 2022
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphomaSanjal H Desai, Raphael Mwangi, Alexandra N Smith, et al.
BMJ (Clinical Research Ed.)|January 27, 2017
Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessmentSpyridoula Maraka, Raphael Mwangi, Rozalina G McCoy, et al.
Blood Advances|February 18, 2025
Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experienceSteven R Hwang, Richard C Godby, Brianna J Negaard, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Blood Cancer Journal|January 15, 2020
High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?Priyanka A Pophali, Lisa M Marinelli, Rhett P Ketterling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?Arushi Khurana, Raphael Mwangi, Grzegorz S Nowakowski, et al.
American Heart Journal|December 25, 2015
Trends and predictors of repeat catheter ablation for atrial fibrillationMohammed A Al-Hijji, Abhishek J Deshmukh, Xiaoxi Yao, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2019
Variation in Treatment Practices for Subclinical Hypothyroidism in Pregnancy: US National AssessmentSpyridoula Maraka, Raphael Mwangi, Xiaoxi Yao, et al.
Blood Advances|September 28, 2022
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosisSanjal H Desai, Raphael Mwangi, Wern Lynn Ng, et al.
Blood Cancer Journal|July 18, 2021
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab eraArushi Khurana, Raphael Mwangi, Stephen M Ansell, et al.
American Journal of Hematology|October 14, 2024
Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screeningSuheil Albert Atallah-Yunes, Matthew J Rees, Raphael Mwangi, et al.
Hematological Oncology|October 28, 2022
Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphomaSanjal H Desai, Raphael Mwangi, Alexandra N Smith, et al.
BMJ (Clinical Research Ed.)|January 27, 2017
Thyroid hormone treatment among pregnant women with subclinical hypothyroidism: US national assessmentSpyridoula Maraka, Raphael Mwangi, Rozalina G McCoy, et al.
Blood Advances|February 18, 2025
Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experienceSteven R Hwang, Richard C Godby, Brianna J Negaard, et al.
Pageof 5